Dogwood Therapeutics, Inc. (DWTX)
1.69
-0.03
(-1.74%)
USD |
NASDAQ |
Sep 18, 16:00
1.70
+0.01
(+0.59%)
After-Hours: 20:00
Dogwood Therapeutics Enterprise Value : 47.35M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 47.35M |
| September 17, 2026 | 48.36M |
| September 16, 2026 | 47.69M |
| September 15, 2026 | 48.70M |
| September 14, 2026 | 52.56M |
| September 11, 2026 | 55.76M |
| September 10, 2026 | 53.74M |
| September 09, 2026 | 55.76M |
| September 08, 2026 | 59.12M |
| September 04, 2026 | 67.53M |
| September 03, 2026 | 69.88M |
| September 02, 2026 | 73.92M |
| September 01, 2026 | 78.96M |
| August 31, 2026 | 77.28M |
| August 28, 2026 | 79.64M |
| August 27, 2026 | 68.54M |
| August 26, 2026 | 79.97M |
| August 25, 2026 | 80.64M |
| August 24, 2026 | 76.61M |
| August 21, 2026 | 74.25M |
| August 20, 2026 | 68.87M |
| August 19, 2026 | 68.20M |
| August 18, 2026 | 62.48M |
| August 17, 2026 | 59.79M |
| August 14, 2026 | 62.82M |
| Date | Value |
|---|---|
| August 13, 2026 | 57.10M |
| August 12, 2026 | 55.25M |
| August 11, 2026 | 52.40M |
| August 10, 2026 | 52.06M |
| August 07, 2026 | 51.22M |
| August 06, 2026 | 49.37M |
| August 05, 2026 | 52.06M |
| August 04, 2026 | 50.71M |
| August 03, 2026 | 48.02M |
| July 31, 2026 | 45.67M |
| July 30, 2026 | 43.65M |
| July 29, 2026 | 42.31M |
| July 28, 2026 | 42.64M |
| July 27, 2026 | 41.97M |
| July 24, 2026 | 40.96M |
| July 23, 2026 | 42.31M |
| July 22, 2026 | 39.62M |
| July 21, 2026 | 37.60M |
| July 20, 2026 | 36.93M |
| July 17, 2026 | 36.93M |
| July 16, 2026 | 36.59M |
| July 15, 2026 | 38.94M |
| July 14, 2026 | 38.61M |
| July 13, 2026 | 36.93M |
| July 10, 2026 | 38.27M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
| Vericel Corp. | 1.980B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.53M |
| Total Expenses (Quarterly) | 11.53M |
| EPS Diluted (Quarterly) | -0.3378 |
| Earnings Yield | -529.6% |
| Normalized Earnings Yield | -518.41 |